The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English (UK)
Deutsch
English (UK)
Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies
NIL
Jahr
Publikationsjahr
2021
Autoren
Autorenliste der Publikation
Saak A, Benkert P, Akgün K, Willemse E, Kuhle J, Ziemssen T, Jackson S, Schaefer J.
Verlag
Publisher-Information
Front Neurosci. 2021 Dec 17;15:791670.
Link
Zur Publikation (externer Server)
https://doi.org/10.3389/fnins.2021.791670
Tags
Forschungsthemen
Neuroimmunologie
Andere
NIL
2021
Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation
NIL
Jahr
2024
Raman Spectroscopy of Optically Trapped Living Human T Cell Subsets and Monocytes
NIL
Jahr
2024
COVID-19 and multiple sclerosis: challenges and lessons for patient care
Multiple Sclerosis
Jahr
2024
Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374
NIL
Jahr
2024
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma
NIL
Jahr
2024